June 2017

New Indications

Fycompa (perampanel (as hemisesquihydrate)) is now indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

INOmax (nitric oxide for inhalation), in conjunction with ventilatory support and other appropriate agents, is now indicated as part of the treatment of perioperative and postoperative pulmonary hypertension in newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction with heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

Kalydeco (ivacaftor) is now indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have an R117H mutation in the CFTR gene.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au